The ulcer crater disappeared completely in 81% of the cases after six weeks and in 92 % after 12 weeks of carbenoxolone.
The dose used in the trial was 100 mg. thrice daily for the first week and 50 mg. thrice daily for the second and subsequent weeks. Treatment should be continued until the ulcer has been shown radiologically to have healed. After complete healing a maintenance dose should be prescribed to prevent recurrence. Attention is also drawn to the drug's side-effects, which occurred in 35 % of patients, and of which salt-and-water retention is the most important. The side-effects led to the introduction of a five-or six-day regime in which carbenoxolone was omitted on one or both days at the week-end in those at risk. Since the introduction of this regime side-effects have been much less marked and less frequent.
Carbenoxolone has a specific effect, facilitating the healing of gastric ulcer, and is not merely yet another symptomatic measure.
We are grateful to the physicians of Whiston Hospital for their help and for allowing us to treat patients under their care; to Dr. S. Gottfried for his assistance; to Biorex Laboratories Ltd. for supplies of trial tablets and carbenoxolone sodium; to Mr. F. M. Sullivan, of Guy's Hospital Medical School, for his assistance with the statistical analysis; and to Mr. E. Thomas, Chief Pharmacist, Whiston Hospital, who distributed the trial tablets.
Frusemide (4 - chloro -N -(2 -furylmethyl) -5 -sulphamoylanthranilic acid; Lasix) is a newly introduced diuretic agent which differs from all other such drugs at present in clinical use. Though a sulphonamide derivative (see Formula), frusemide does not closely resemble chlorthalidone or the benzothiadiazine drugs chemically or pharmacologically (Stewart, 1965) . Frusemide may be given orally or parenterally; by either route it produces a rapid, short-lived diuresis due to inhibition of salt-and-water reabsorption in both proximal and distal portions of the renal tubule (Suzuki, Kliltsch, and Heidland, 1964) . Several clinical trials in oedematous patients have shown that frusemide causes a greater natriuresis than other commonly used diuretic drugs. In doses ranging from 25 to 100 mg. it is superior to an equal dose of hydrochlorothiazide (Kleinfelder, 1963; Stokes and Nunn, 1964 ; Verel, Stentiford, Rahman, and Saynor, 1964) . Stokes and Nunn (1964) 
Clinical Material and Methods
Eleven patients were studied. Each had been admitted to hospital for the treatment of oedema which had failed to improve with ordinary diuretic therapy. Relevant clinical data on these patients are shown in Table I . Of the 11 patients, one had portal hypertension, two had the nephrotic syndrome, and eight had congestive heart failure due to various causes. All but four patients had some impairment of renal function.
Each patient was weighed daily at 8 a.m., and accurate 8 a.m. to 8 a.m. fluid-balance charts were kept. The volume and sodium, potassium, and chloride content of each 24-hour collection of urine were measured. Serum and urinary electrolytes and serum urea nitrogen concentrations were determined on the Technicon AutoAnalyzer, and creatinine was measured by the method of Edwards and Whyte (1958) .
Design of Clinical Trials
All patients were given a diet containing 3 g. of salt (approximately 50 mEq of Na) and allowed 1 litre of drinking-fluids each day. The diuretic drugs were given daily at 10 a.m. in a single oral dose unless otherwise stated, except spironolactone, which was given in four equal doses daily. In trials A, B, and C only one diuretic drug was given each day. Fig. 3 . The results from the first two days of spironolactone treatment were omitted from the trial.
Trial E.-Six patients were treated with frusemide in two or more different doses. The scheme of dose rotation was variable, but the ABBA plan was closely followed. Three of the patients were also given other diuretic drugs at a constant dose throughout the trial (see Table V ).
Results
The natriuretic potency of frusemide (Table II With few exceptions potassium excretion (Table III) was increased over control-values by all diuretic drugs other than mersalyl. Potassium loss was related to natriuretic efficacy by determining the urinary sodium/potassium ratio (Table III) .
In trial A, in which the results were statistically significant, frusemide and ethacrynic acid caused the least mean potassium loss and the highest mean urinary sodium/potassium ratio, and bendrofluazide the greatest mean potassium loss and lowest mean urinary sodium/potassium ratio. In trials B and C the urinary potassium excretion after mersalyl was less than that after frusemide, but the sodium/potassium ratios were not significantly different.
In trial A weight change and daily urine volume were altered by the different diuretic drugs in much the same manner as was urinary sodium loss (Table IV ). An exception was the proportionately greater weight loss after ethacrynic acid than after the other treatments. The urinary excretion of chloride was increased by a greater amount than that of sodium by each of the treatments, particularly by ethacrynic acid, and the excretion of anions other than chloride (determined approximately from urinary Na+K-Cl) was lower after frusemide or ethacrynic acid than in the control period, but higher after bendrofluazide (Table IV) . The exhibition of frusemide to a patient already taking spironolactone increased urinary sodium excretion (trial D, Case 8), and the response to frusemide could be improved by adding spironolactone to the treatment (Fig. 3) . In trial E, increasing the dose of frusemide within the range from 40 to 240 mg. (Table V) caused an approximately linear increase in sodium excretion in the diuretic responsive patients (Cases 1, 11, and 4), but there was much less change in the diuretic resistant patients (Cases 9, 10, and 2). The results show that frusemide is a highly potent saluretic agent. The efficacy of frusemide, and, to a lesser extent, of ethacrynic acid, was underestimated in comparison with bendrofluazide and mersalyl, for the latter two drugs were given in maximally effective doses for oedematous subjects (Swartz, Seller, Fuchs, Brest, and Moyer, 1963 ; Clarke, Modell, Greiner, Kwit, Gluck, and Gold, 1950) . In non-oedematous subjects the maximally effective dose of frusemide is rather more than 150 mg. (Timmerman, Springman, and Thoms, 1964) , and that of ethacrynic acid is 200 mg. (Melvin, Farrelly, and North, 1963) , but in diuretic-responsive oedematous patients the maximally effective dose of these two drugs may well be higher, as suggested for ethacrynic acid in our own pilot study, by Foltz (1963) , and by Maher, O'Connell, Setter, and Schreiner (1964) , and for frusemide by the results of trial E. Moreover, frusemide has a duration of action of only four hours (Fig. 2) , whereas that of ethacrynic acid (Melvin et al., 1963) , bendrofluazide (Ford and Nickell, 1960) , and mersalyl (Fig. 2) is about 12 hours. In theory frusemide in maximally effective doses could be repeated much more frequently than the other drugs, but in practice a single 80-200-mg. dose of frusemide caused as much fluid loss as our rather ill patients could tolerate.
Three patients (Cases 9, 10, and 2 in trial E) responded poorly to frusemide, presumably because of moderate renal impairment (Table I) . Non-oedematous patients with renal impairment, when given frusemide (Heidland, Kliitsch, and Suzuki, 1964; Vorburger, 1964) or chlorothiazide or meralluride (Reubi and Cottier, 1961) , responded by increasing urinary sodium excretion by an amount proportional to the glomerular filtration rate. With each of these drugs a detectable natriuresis was obtained in all patients whose glomerular filtration rate was more than 10 ml./min., but the response to frusemide was greater than that to the other drugs. Since the response to frusemide of patients with renal impairment is improved by raising the dose , it would be reasonable to use larger doses-for example, 200-400 mg./ day-when conventional doses prove inadequate in these circumstances. Ethacrynic acid caused a diuresis in nearly all oedematous patients with renal disease and glomerular filtration rates as low as 6 ml./min. (unpublished observations on patients reported by Edwards, Sinnett, and Stewart, 1964) . Patients with gross oedema sometimes responded poorly or transiently to frusemide, but when the oedema was not associated with renal circulatory impairment or intrinsic renal disease diuresis was usually induced by giving spironolactone in addition to frusemide.
Frusemide resembles ethacrynic acid and mersalyl in that it causes little increase in the excretion of potassium or of anions other than chloride as determined by (Na+K-Cl). Though the dietary content of minerals and protein was not strictly controlled, the design of trial A, by intermingling the treatments, would have eliminated the error due to any fluctuations in food intake. In this trial, in which there were many randomized treatment periods, it is probable that variations in the day-today excretion of non-buffer ions-for example, Ca++, Mg++, and S04"-were equally distributed between the different treatments, and that most of the between-treatment differences in urinary (Na + K-Cl) were due to the effect of the diuretic drugs on the excretion of buffer anions, particularly bicarbonate and/or of hydrogen and ammonium ions. The conclusion from these results that frusemide causes less net excretion of base than does bendrofluazide accords with the demonstration in vitro that frusemide does not inhibit carbonic anhydrase (Muschaweck and Haidui, 1964) . Though there are no published reports describing either presence or absence of in vitro inhibition of carbonic anhydrase by ethacrynic acid, the extensive clinical investigation of this drug undertaken by Cannon, Ames, and Laragh (1963) leaves little doubt that ethacrynic acid has no significant inhibitory effect on carbonic anhydrase. The excess excretion of chloride over that of sodium and potassium resulting from the administration of ethacrynic acid, and to a lesser extent of frusemide, may induce hypochloraemic alkalosis when these drugs are given for long periods. Few patients, except those with hepatic cirrhosis, require supplementary potassium therapy while taking frusemide (Kleinfelder, 1963; Stokes and Nunn, 1964; Vorburger, 1964) .
Acute studies on animals (Muschaweck and Hajdu', 1964) and clinical trials of frusemide treatment continued for several months (Kleinfelder, 1963 ; Stokes and Nunn, 1964 ; Verel et al., 1964 ) have failed to demonstrate any toxic effects from ordinary doses of frusemide. Frusemide appears to have no diabetogenic action (Schaefer, 1964 difference.-There is obviously no significant difference in these symptoms between the two groups. An alteration in the duration of early-morning stiffness was assumed to be of clinical significance if it exceeded 30 minutes. In the first month, on phenylbutazone, there was improvement in the loosening-up time in seven patients and deterioration in one, five being unchanged. On indomethacin there was improvement in three, deterioration in four, and no change in six. These changes are not statistically significant (X2=1.4 ; n = 1; 0.3>P>0.2). In the second month, on indomethacin, improvement occurred in three patients, and this parameter worsened in two, eight exhibiting no change. On phenylbutazone there was no change in six, four improved, and three deteriorated.
A difference in grip strength of 50 mm. of mercury was assumed to be clinically significant. In the first month, on phenylbutazone, none improved, five deteriorated, and eight remained unchanged. On indomethacin three improved, one deteriorated, and there was no change in nine. There was no statistically significant difference between the groups (x2= 1.5; n= 1; 0.3>P>0.2). In the second month, on indomethacin, 11 patients remained unchanged, one improving, and one deteriorating. In comparison, on phenylbutazone, there was no change in 10 patients, improvement occurring in three. There was obviously no significant difference.
As 17 of the 26 patients had no tender joints at any time during the trial this was an unsatisfactory parameter.
